Prices are updated after-hours

Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

tags : Lenzilumab    symbols : EBS    save search

Humanigen and Emergent BioSolutions Announce Contract Development and Manufacturing Agreement for Phase 3 COVID-19 Therapeutic Candidate Lenzilumab™
Published: 2021-01-25 (Crawled : 18:00) - biospace.com/
EBS F | $1.98 -3.88% -2.53% 1M twitter stocktwits trandingview |
Health Technology
| | O: 0.0% H: 0.0% C: -0.7%
HGEN | $0.0361 -61.5% 120M twitter stocktwits trandingview |
Health Technology
| | O: 0.71% H: 1.32% C: -2.74%

covid contract phase 3 merge lenzilumab
Gainers vs Losers
47% 53%

Top 10 Gainers
KAVL | $6.3 135.96% 57.45% 44M twitter stocktwits trandingview |
Wholesale Trade

PXMD | $0.74 79.7% 44.16% 4.5M twitter stocktwits trandingview |
Health Technology

DYNT | $0.3704 -5.27% 43.09% 1.6M twitter stocktwits trandingview |
Health Technology

LGVN P 3 d | $2.93 73.37% 42.52% 56M twitter stocktwits trandingview |

HUBC | $1.95 50.0% 32.99% 73M twitter stocktwits trandingview |
n/a

SPCB | $0.4004 45.07% 31.75% 130M twitter stocktwits trandingview |
Electronic Technology

ONVO | $1.35 33.65% 24.62% 53M twitter stocktwits trandingview |
Health Technology

OMQS | $0.7038 35.35% 24.3% 3.5M twitter stocktwits trandingview |
Professional, Scientific, and T...

SNPO | $10.54 29.48% 22.88% 3.9M twitter stocktwits trandingview |

EEIQ | $1.16 27.46% 20.86% 6.9K twitter stocktwits trandingview |
Educational Services


Your saved searches
Save your searches and get alerts when important news are released.